Phase 2 is named as an intervention in 3 current clinical trials in our USA, UK, China, Germany, France, Spain, Italy, Canada, South Korea, Taiwan and Australia registers. 3 are recruiting patients now. All registered phases are Phase 1/2. The sponsor with the most trials is enGene, Inc (1). The most-studied condition is Superficial Bladder Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722 · ClinicalTrials.gov ↗ · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
|
Phase 1/2 | Recruiting | enGene, Inc | UK, USA, China, Germany, France, Spain, Italy, Canada, South Korea, Taiwan, Australia |
|
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06578624 · Solid Tumor
|
Phase 1/2 | Recruiting | Lamassu Bio Inc | USA |
|
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
NCT07357519 · Relapsed / Refractory Osteosarcoma
|
Phase 1/2 | Recruiting | Lantheus Medical Imaging | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| enGene, Inc | 1 |
| Lamassu Bio Inc | 1 |
| Lantheus Medical Imaging | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, UK, China, Germany, France, Spain, Italy, Canada, South Korea, Taiwan and Australia registers name Phase 2 (also registered as EG-70) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in USA, 1 with sites in UK, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Canada, 1 with sites in South Korea, 1 with sites in Taiwan and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
enGene, Inc (1), Lamassu Bio Inc (1) and Lantheus Medical Imaging (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Phase 2 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Phase 2 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Phase 2 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.